Publikationen
Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery; FASEB J. 33, 9235–9249 (2019) ,Poser, S. W., Otto, O., Arps‐Forker, C., Ge, Y., Herbig, M., Andree, C., Gruetzmann, K., Adasme, M. F., Stodolak, S., Nikolakopoulou, P., Park, D. M., Mcintyre, A., Lesche, M., Dahl, A., Lennig, P., Bornstein, S. R., Schroeck, E., Klink, B., Leker, R. R., Bickle, M., Chrousos, G. P., Schroeder, M., Cannistraci, C. V., Guck, J., Androutsellis‐Theotokis, A.A https://doi.org/10.1096/fj.201802603RR
Efficient inhibition of HSP27, Schroeder, Michael; Zhang, Yixin; Heinrich, Joerg-Christian; Haupt, Joachim; Donakonda, Sainitin; Lennig, Petra PCT Int. Appl. (2016), WO 2016016267 A1 20160204
Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27, Schroeder, Michael; Zhang, Yixin; Heinrich, Joerg-Christian; Haupt, Joachim; Donakonda, Sainitin; Lennig, Petra PCT Int. Appl. (2016), WO 2016016268 A1 20160204
New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells, Heinrich Jorg C; Donakonda Sainitin; Haupt V Joachim; Schroeder Michael; Lennig Petra; Zhang Yixin https://doi.org/10.18632/oncotarget.11905